Iterum Therapeutics shares are trading higher after the FDA acknowledged receipt of the company's resubmission of its New Drug Application for oral sulopenem.
Portfolio Pulse from Benzinga Newsdesk
Iterum Therapeutics shares are trading higher after the FDA acknowledged receipt of the company's resubmission of its New Drug Application for oral sulopenem.
May 31, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iterum Therapeutics shares are trading higher following the FDA's acknowledgment of the company's resubmission of its New Drug Application for oral sulopenem.
The FDA's acknowledgment of the resubmission is a positive regulatory development, which has led to an increase in Iterum Therapeutics' share price. This indicates investor optimism about the potential approval of oral sulopenem.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100